Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE

GlobeNewswire March 18, 2020

EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

GlobeNewswire March 18, 2020

Global Markets Are In Turmoil Sending Investors Scrambling For A Safe Haven

Livemoney March 13, 2020

Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire February 27, 2020

Vaxart Announces Initiation of Coronavirus Vaccine Program

GlobeNewswire January 31, 2020

Results from Influenza Challenge Study Published in Lancet Infectious Diseases

GlobeNewswire January 22, 2020

Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2019

Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease

GlobeNewswire November 6, 2019

Vaxart, Inc. Announces Changes to its Board of Directors

GlobeNewswire October 28, 2019

Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019

GlobeNewswire October 1, 2019

Vaxart Announces Pricing of $8 Million Underwritten Public Offering

GlobeNewswire September 26, 2019

Vaxart's Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study

GlobeNewswire September 25, 2019

Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Business Wire September 4, 2019

Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Business Wire August 8, 2019

Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine

Business Wire July 9, 2019

Vaxart to Present at ASM Microbe 2019

Business Wire June 20, 2019

New Publication in Vaccine Highlights Preclinical Results of Vaxart's Mucosal Chikungunya Vaccine

Business Wire May 29, 2019

Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update

Business Wire May 9, 2019

Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Business Wire April 16, 2019

Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

Business Wire April 12, 2019